Acceleron Pharma

Acceleron Reports Second Quarter 2020 Operating and Financial Results

Retrieved on: 
Thursday, August 6, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical trials, Other Health, Acceleron Pharma, Luspatercept, Health care, Companies, Health

Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.
  • Recently, we presented positive topline results from the Phase 2 PULSAR trial at the countrys premiere thoracic medical meeting, ATS 2020.
  • The Company recognized approximately $11.1 million in royalty revenue from approximately $55.0 million of net U.S. sales of REBLOZYL in the second quarter of 2020.
  • The Company will host a webcast and conference call to discuss its second quarter 2020 financial results and provide an update on recent corporate activities on August 6, 2020, at 5:00 p.m. EDT.

Acceleron to Webcast Second Quarter 2020 Operating and Financial Results on August 6, 2020

Retrieved on: 
Monday, July 27, 2020
Science, Cardiology, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Acceleron Pharma, Pulmonary hypertension, Hypertension, Health, Companies, Branches of biology

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 6, 2020 at 5:00 p.m. EDT to discuss its second quarter 2020 operating and financial results.

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 6, 2020 at 5:00 p.m. EDT to discuss its second quarter 2020 operating and financial results.
  • The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial.

Acceleron Appoints Christopher Hite to its Board of Directors

Retrieved on: 
Thursday, June 4, 2020
Health, Infectious diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Acceleron Pharma, Companies, Economy of the United States

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Christopher Hite to its Board of Directors.

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Christopher Hite to its Board of Directors.
  • Im thrilled that Chris is joining our Board, as his background and accomplishments make him a particularly strong addition, said Francois Nader, M.D., Chairman of Acceleron Pharma.
  • For more than 24 years, Mr. Hite advised hundreds of healthcare companies on projects ranging from mergers and acquisitions to capital formation.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.

Acceleron to Webcast First Quarter 2020 Operating and Financial Results on May 11, 2020

Retrieved on: 
Tuesday, May 5, 2020
Biotechnology, Pharmaceutical, Health, Cardiology, Acceleron Pharma, Pulmonary hypertension, Companies

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Monday, May 11, 2020 at 5:00 p.m. EDT to discuss its first quarter 2020 operating and financial results.

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Monday, May 11, 2020 at 5:00 p.m. EDT to discuss its first quarter 2020 operating and financial results.
  • The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial.

Acceleron Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Sotatercept in Pulmonary Arterial Hypertension

Retrieved on: 
Monday, May 4, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Acceleron Pharma, Pulmonary hypertension, PAH, Companies, Orphan drugs, Pyrimidines, Health care, United Therapeutics, Health, Sulfonamides, Sotatercept, PAH, Acceleron

Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH).

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH).
  • In 2019, the FDA granted Orphan Drug designation for sotatercept in PAH.
  • In preclinical studies of PAH, sotatercept reversed pulmonary vessel muscularization and improved indicators of right heart failure.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial.

Acceleron Announces Retirement of Director Jean George

Retrieved on: 
Tuesday, April 7, 2020
Biotechnology, Pharmaceutical, Health, Acceleron Pharma, Companies

As one of Accelerons longest-serving Board members, Jean has been instrumental in helping to guide the Company toward its current position of strength, said Francois Nader, MD, Chairman of Acceleron Pharma.

Key Points: 
  • As one of Accelerons longest-serving Board members, Jean has been instrumental in helping to guide the Company toward its current position of strength, said Francois Nader, MD, Chairman of Acceleron Pharma.
  • Prior to joining ATV, Ms. George was a Director at BancBoston Ventures, where she led the teams investment activity in multiple health care portfolio holdings.
  • I have been fortunate to work alongside Jean throughout my three and a half-year tenure as CEO, said Habib Dable, President and Chief Executive Officer of Acceleron.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.

Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease

Retrieved on: 
Monday, March 9, 2020
Biotechnology, Health, Pharmaceutical, Dental, Clinical trials, Hypertension, Pulmonary hypertension, RTT, Acceleron Pharma

We wish to thank all of the patients, families, caregivers, and investigators for their support and participation in this research.

Key Points: 
  • We wish to thank all of the patients, families, caregivers, and investigators for their support and participation in this research.
  • In this Phase 2 trial in patients with CMT, ACE-083 was generally well tolerated.
  • Acceleron plans to present results of the study at the American Academy of Neurology Annual Meeting in April.
  • Acceleron is also developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial and actively enrolling patients in the Phase 2 SPECTRA trial.

Acceleron to Participate in Two Upcoming Healthcare Investor Conferences

Retrieved on: 
Wednesday, February 26, 2020
Health, Genetics, Other Science, Research, Science, Pharmaceutical, Biotechnology, Acceleron Pharma, Companies, Economy of the United States

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences.

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences.
  • A replay of each webcast will be available approximately two hours after the event on the Acceleron website.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.
  • Acceleron focuses its research and development efforts in hematologic, pulmonary, and neuromuscular diseases.

Acceleron to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on February 27, 2020

Retrieved on: 
Tuesday, February 18, 2020
Biotechnology, Pharmaceutical, Health, Acceleron Pharma, Branches of biology, Myostatin

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 27, 2020 at 5:00 p.m. EST to discuss its fourth quarter and full year 2019 operating and financial results.

Key Points: 
  • Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 27, 2020 at 5:00 p.m. EST to discuss its fourth quarter and full year 2019 operating and financial results.
  • The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.
  • Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.
  • The company is also advancing its neuromuscular program with ACE-083, a locally-acting Myostatin+ agent in Phase 2 development in Charcot-Marie-Tooth disease.

John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer

Retrieved on: 
Tuesday, January 28, 2020
Acceleron Pharma, HEPC

Dr. Quisel joins Disc Medicine after more than a decade at Acceleron Pharma where he most recently was Chief Business Officer.

Key Points: 
  • Dr. Quisel joins Disc Medicine after more than a decade at Acceleron Pharma where he most recently was Chief Business Officer.
  • "We are delighted that John will be leading Disc Medicine as we advance first-in-class therapies targeting the hepcidin pathway into the clinic," said Don Nicholson, Chairman of the Board.
  • "Disc Medicine has an extraordinary team that has made significant progress in just a short time.
  • "I am very excited to take on this new role at Disc Medicine as the company advances two novel programs targeting hepcidin biology," said John Quisel, JD, PhD, CEO of Disc Medicine.